<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04245930</url>
  </required_header>
  <id_info>
    <org_study_id>E2019453</org_study_id>
    <nct_id>NCT04245930</nct_id>
  </id_info>
  <brief_title>Bovine Pericardial Patch and TiLOOP® Bra Mesh in Immediate Implant Breast Reconstruction.</brief_title>
  <official_title>A Randomized and Controlled Study of Efficacy and Safety of Bovine Pericardial Patch and TiLOOP® Bra Mesh in Patients With Immediate Implant Breast Reconstruction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is the first randomized and controlled study assessing the efficacy and safety of
      bovine pericardial patch and TiLOOP® bra mesh in patients with immediate implant breast
      reconstruction
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complication Rates</measure>
    <time_frame>up to 12 months after surgery</time_frame>
    <description>The rate of complications in the two groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction-Breast-Q questionnaire</measure>
    <time_frame>up to 12 months after surgery</time_frame>
    <description>We use the Breast-Q questionnaire to evaluate patients' satisfaction via the reconstruction module of BREAST-Q.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic outcome of reconstructed breast</measure>
    <time_frame>Immediately, up to 3 months, 6 months and 12 months after surgery</time_frame>
    <description>Harris evaluation score was used to evaluate the aesthetic outcome of patients' reconstructed breasts, which was scored as &quot;excellent,&quot; &quot;good,&quot; &quot;fair,&quot; &quot;poor&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of surgical revision of reconstructed breasts</measure>
    <time_frame>up to 12 months after surgery</time_frame>
    <description>To record the rate of surgical revision events of the reconstructed breasts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics-inpatient cost</measure>
    <time_frame>up to 12 months after surgery, including the cost of surgical revision</time_frame>
    <description>Hospital inpatient costs due to immediate implant breast reconstruction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Implant Breast Reconstruction</condition>
  <condition>TiLOOP® Bra Mesh</condition>
  <condition>Bovine Pericardial Patch</condition>
  <arm_group>
    <arm_group_label>Bovine Pericardial Patch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immediate implant breast reconstruction using bovine pericardial patch. n=88</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TiLOOP® Bra Mesh</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate implant breast reconstruction using TiLOOP® Bra Mesh. n=88</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bovine Pericardial Patch in Immediate Implant Breast Reconstruction</intervention_name>
    <description>Patients will receive immediate breast implant reconstruction using Bovine Pericardial Patch</description>
    <arm_group_label>Bovine Pericardial Patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TiLOOP® Bra Mesh in Immediate Implant Breast Reconstruction</intervention_name>
    <description>Patients will receive immediate breast implant reconstruction using TiLOOP® Bra Mesh</description>
    <arm_group_label>TiLOOP® Bra Mesh</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients diagnosed with I~II stage breast cancer and Intent to receive NSM or SSM and
             implant based breast reconstruction

          2. Do not smoking in the last 4 weeks or more

          3. Mental health patients

          4. Signed consent to participate

        Exclusion Criteria:

          1. Locally advanced stage patients or patients with distal metastasis

          2. Patients received thoracic wall radiotherapy or will receive radiotherapy

          3. Smoking in the last 4 weeks

          4. Anticipated implant volume more than 600cc

          5. Patients of pregnancy or lactation

          6. Patients received neoadjuvant therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Yin, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunyong Han, MD.</last_name>
    <phone>+86-22-23340123</phone>
    <phone_ext>1174</phone_ext>
    <email>hancy_007@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jian Yin, MD.</last_name>
    <phone>+86-22-23340123</phone>
    <phone_ext>1171</phone_ext>
    <email>yinjian@tjmuch.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunyong Han, MD.</last_name>
      <phone>+86-22-23340123</phone>
      <phone_ext>1174</phone_ext>
      <email>hancy_007@126.com</email>
    </contact>
    <investigator>
      <last_name>Jian Yin, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

